Stivarga approved for GIST

Stivarga (regorafenib) has been approved for the treatment of GIST (GI stromal tumors) in patients with unresectable disease who have failed other treatments. 

Kadcyla now approved for HER positive breast cancer

Kadcyla (ado-trastuzumab emtansine) has been approved for the treatment of HER 2 positive metastatic breast cancer in patients who have not responded to Herceptin (trastuzumab) with chemotherapy. 

Pomalidomide is new drug for Multiple Myeloma

Pomalyst (pomalidomide) has been approved for the treatment of relapsed and/or refractory Multiple Myeloma in patients who have received 2 prior therapies including Revlimid and Velcade and have had disease progression on or within 60 days of completion of their last therapy. 

Generic Doxil to relieve shortage

The FDA has now approved the generic form of Doxil which should help relieve shortages of the brand-name medication.

New indication for Gleevec

Gleevec (imatinib) is now approved for the treatment of pediatric Philadelphia chromosome positive ALL.

Pazopanib approved for soft tissue sarcoma

Votrient (pazopanib), an oral tyrosine kinase inhibitor, has been approved for the treatment of advanced soft tissue sarcoma in patients who have received prior chemotherapy.